Genocea tackles next-gen pneumococcus vaccine

Xconomy's Luke Timmerman profiles the work of Genocea Biosciences, which is developing a low-cost, next-gen pneumococcus vaccine that can outperform the blockbuster Prevnar. Seattle-based PATH has been backing the development program with money from the Gates Foundation. PATH has put up $1 million for a three-year program at Genocea to find new antigens that can be used in a vaccine. Their goal is to do better than Prevnar, which works against only seven of the 80 different types of pneumococcus bacteria. And they want to do it at about $3.50 a dose so that it can be widely available in the developing world. Genocea was a 2008 Fierce 15 winner.

- read the report from Xconomy

Suggested Articles

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Sanofi's cost cuts are adding up, execs said in an update Wednesday. The company has trimmed nearly €1 billion in annual expenses so far in 2020.

Shingrix sales in the second quarter plummeted by half from first-quarter levels, and recovery of vaccination rates remains slow amid the pandemic.